DDIT3 and diffuse large B-cell lymphoma: These observations compared favorably with various previous reports of R-CHOP for DLBCL in a frontline setting and among them with data from the same study group, which had shown a 24-month failure rate of 44% for those receiving R-CHOP within less than 15 days from diagnosis and 28% for those who received treatment later [86].